Study of CCL21 Gene-Modified Dendritic Cells for Lung Cancer Treatment
Author Information
Author(s): Baratelli Felicita, Takedatsu Hiroko, Hazra Saswati, Peebles Katherine, Luo Jie, Kurimoto Pam S, Zeng Gang, Batra Raj K, Sharma Sherven, Dubinett Steven M, Lee Jay M
Primary Institution: UCLA Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center
Hypothesis
Intratumoral injection of CCL21-gene modified dendritic cells (CCL21-DC) will stimulate specific immune responses without excluding patients based on HLA phenotype.
Conclusion
Viable and biologically active clinical grade CCL21 gene-modified dendritic cells can be generated from cryopreserved PBMC.
Supporting Evidence
- Transduction of dendritic cells with CCL21 led to secretion of biologically active CCL21.
- CCL21-DC maintained high viability and integral biological activities.
- Supernatants from CCL21-DC induced chemotaxis of T2 cells in vitro.
- CCL21-DC demonstrated an immature phenotype and retained antigen presentation capabilities.
- CCL21-DC secreted functional CCL21 capable of inducing chemotaxis.
Takeaway
The researchers found a way to create special immune cells that can help fight lung cancer by using a gene called CCL21.
Methodology
Human monocyte-derived dendritic cells were differentiated and transduced with a clinical grade adenoviral vector encoding CCL21.
Limitations
The study primarily focuses on pre-clinical data and may not fully predict clinical outcomes.
Participant Demographics
Healthy volunteers provided mononuclear cells for the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website